Clinical trial
Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic…
NCT00005873 · Astex Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00005873 |
|---|---|
| Title | Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer |
| Official title | Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Relapsed Metastatic Breast Cancer |
| Lead sponsor | Astex Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | rubitecan |
| Start date | Sep 1, 1999 |
| Completion | Apr 1, 2004 |
| First posted | Apr 13, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: